Navigation Links
Bionovo to Present at the Piper Jaffray Healthcare Conference
Date:12/2/2008

EMERYVILLE, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective drugs in the areas of women's health and cancer, announced that Isaac Cohen, Chairman and CEO of Bionovo, will be presenting an overview of the Company at the 20th Annual Piper Jaffray Health Care Conference at 8 a.m. EST on December 3, 2008. The event will be held at the New York Palace Hotel in New York City.

The presentation will be webcast and can be viewed via Bionovo's website at http://bionovo.com/investors/events or http://www.piperjaffray.com/conferences.

A webcast replay will become available shortly after the presentation ends and will continue to be accessible for a short period via Bionovo's website.

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board
2. Bionovo Reports Third Quarter 2008 Financial Results
3. Bionovo to Present at Merriman Curhan Fords Investor Summit 2008 on September 15th
4. Bionovo to Present at Canaccord Adams Global Growth Conference
5. Bionovo Reports Second Quarter 2008 Financial Results
6. Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
7. Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds
8. Bionovo Reports First Quarter 2008 Financial Results
9. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
10. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
11. Louis Drapeau Joins Bionovos Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017  Market Research Future has a half ... for Liquid Biopsy is growing rapidly and expected to reach USD ... Market Highlights ... Global Liquid Biopsy Market has been assessed as a swiftly growing ... and boom in the coming future. There has been a tremendous ...
(Date:1/19/2017)... ... January 19, 2017 , ... November ... to leading biopharmaceutical and medical device manufacturers and regulators, is proud to announce ... Part 11-compliant email client designed to provide product vigilance departments with the flexibility ...
(Date:1/19/2017)... ... January 18, 2017 , ... LabRoots , ... from around the world, was today awarded the "Best Science & Technology Social ... on merit and decided upon by a dedicated team of researchers and analysts. ...
(Date:1/19/2017)... , Jan. 18, 2017 Acupath Laboratories, ... announces the formation of an Executive Committee that will ... beyond. John Cucci , a 15-year ... from Director of Business Development to Chief Sales ... Mr. Cucci served in senior sales leadership roles at ...
Breaking Biology Technology:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
(Date:1/6/2017)... Colo. , Jan. 5, 2017  SomaLogic ... the "Digital Life Alliance" established by iCarbonX, the ... 2015 to build a "Global Digital Health Ecosystem ... on a combination of individual,s biological, behavioral and ... the agreement between the companies, SomaLogic will provide ...
Breaking Biology News(10 mins):